» Articles » PMID: 27749322

Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor MRNA in Stabilized Whole Blood, As a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients

Overview
Journal Cancer J
Specialty Oncology
Date 2016 Oct 18
PMID 27749322
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample collection, processing, and analysis, we compared detection rates of CellSearch performed using US Food and Drug Administration-cleared methodology with a second positive selection assay, AdnaTest, and a nonselection polymerase chain reaction (PCR)-based (direct detection PCR [DDPCR]) assay in 55 blood samples from 47 men with progressive metastatic castration-resistant prostate cancer. AdnaTest requires processing within 4 hours of the draw and detects KLK3, PSMA, and EGFR transcripts in cells captured on magnetic beads. The DDPCR assay can be processed up to 7 days after a draw and detects KLK2, KLK3, HOXB13, GRHL2, and FOXA1 genes. AdnaTest and DDPCR were considered positive if at least 1 transcript was detected. AdnaTest detected CTCs in 34 samples (62%; 95% confidence interval [CI], 48%-75%), of which 23 (68%) had unfavorable CTC counts by CellSearch. A positive DDPCR result was seen in 38 cases (69%; 95% CI, 55%-81%), including 24 (63%) with unfavorable CellSearch CTC counts. CellSearch found unfavorable CTC counts in 25 samples (45%; 95% CI, 33%-58%). Sensitivities were similar between the AdnaTest and DDPCR assays, and both were more sensitive than CellSearch. Concordance probability estimates (possible values, 0.5-1.0) associating the biomarker result with survival were similar: 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Overall detection rates between the AdnaTest and DDPCR assays were similar, and both were superior to CellSearch. The DDPCR assay required the lowest blood volume, least on-site processing, and longest stability for batch processing.

Citing Articles

Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).

Rusnakova D, Aziri R, Dubovan P, Jurik M, Mego M, Pindak D Oncol Lett. 2024; 29(1):10.

PMID: 39492933 PMC: 11526295. DOI: 10.3892/ol.2024.14756.


Microfluidic Applications in Prostate Cancer Research.

Szewczyk K, Jiang L, Khawaja H, Miranti C, Zohar Y Micromachines (Basel). 2024; 15(10).

PMID: 39459070 PMC: 11509716. DOI: 10.3390/mi15101195.


Mitophagy related diagnostic biomarkers for coronary in-stent restenosis identified using machine learning and bioinformatics.

Shen M, Chen M, Chen Y, Yu Y Sci Rep. 2024; 14(1):24137.

PMID: 39406802 PMC: 11480419. DOI: 10.1038/s41598-024-74862-y.


EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients.

Perelmuter V, Grigoryeva E, Savelieva O, Alifanov V, Andruhova E, Zavyalova M Sci Rep. 2024; 14(1):12245.

PMID: 38806508 PMC: 11133449. DOI: 10.1038/s41598-024-61516-2.


Detection of circulating tumor cells by means of machine learning using Smart-Seq2 sequencing.

Pastuszak K, Sieczczynski M, Dziegielewska M, Wolniak R, Drewnowska A, Korpal M Sci Rep. 2024; 14(1):11057.

PMID: 38744942 PMC: 11094170. DOI: 10.1038/s41598-024-61378-8.


References
1.
de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

2.
Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

3.
Danila D, Anand A, Schultz N, Heller G, Wan M, Sung C . Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol. 2013; 65(6):1191-7. PMC: 4113474. DOI: 10.1016/j.eururo.2013.07.006. View

4.
Kelloff G, Sigman C, Scher H . Biomarker development in the context of urologic cancers. Urol Oncol. 2015; 33(6):295-301. PMC: 4521394. DOI: 10.1016/j.urolonc.2015.01.007. View

5.
Shaffer D, Leversha M, Danila D, Lin O, Gonzalez-Espinoza R, Gu B . Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(7):2023-9. DOI: 10.1158/1078-0432.CCR-06-2701. View